PGx paclitaxel

The result is reported as the CYP2C8 genotype: heterozygous *1/*3, homozygous *3/*3, or *1/*1 with no *3 detected. No consensus framework translates CYP2C8 genotype into a metaboliser phenotype for paclitaxel, so none is assigned; any guidance that later emerges is held in the databases linked below rather than fixed on this page.

A negative result reflects only *3 and does not exclude reduced function from other alleles such as *2 or *4, or from copy-number and structural variation, none of which *3-targeted genotyping detects.

The EU product information for the albumin-bound product names CYP2C8 and CYP3A4 as the metabolising enzymes and advises caution with concomitant inhibitors and inducers, but requires no CYP2C8 genotyping and defines no genotype-based dose adjustment; the US label is concordant. No pharmacogenomic consortium or oncology society has issued a guideline for this gene to drug pair, and no paclitaxel label carries a pharmacogenomic annotation for CYP2C8; the annotations held in the maintained databases sit at their lower evidence levels and record a reported association rather than an actionable one. The clinical utility of genotyping is therefore not established.

For current information consult the prescribing information for paclitaxel, the gene resource and . The result is interpreted in the individual clinical context, and the treatment decision rests with the treating physician.

Content reviewed against the current product information and database entries on 28 July 2026. Classifications are revised periodically; the linked databases hold the day-current version.

• Bergmann TK, Brasch-Andersen C, Green H, Mirza M, Pedersen RS, Nielsen F, et al. Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenomics J. 2011;11(2):113-20. doi: 10.1038/tpj.2010.19. PMID: .
• Guijosa A, Freyria A, Espinosa-Fernandez JR, Estrada-Mena FJ, Armenta-Quiroga AS, Ortega-Treviño MF, et al. Pharmacogenetics of taxane-induced neurotoxicity in breast cancer: Systematic review and meta-analysis. Clinical and translational science. 2022;15(10):2403-2436. doi: 10.1111/cts.13370. PMID: . PMCID: PMC9579387.
• 1000 Genomes Project Consortium, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, et al. A global reference for human genetic variation. Nature. 2015;526(7571):68-74. doi: 10.1038/nature15393. PMID: . (European-ancestry allele frequency for rs11572080 and rs10509681, phase 3.)
• European Medicines Agency. Abraxane (paclitaxel formulated as albumin-bound nanoparticles) EPAR product information, Summary of Product Characteristics section 4.5. Current version 21 January 2026.
• US Food and Drug Administration. ABRAXANE (paclitaxel protein-bound particles for injectable suspension) prescribing information, section 7 Drug Interactions (NDA021660, version 37). Effective 31 October 2022.